The estimated Net Worth of Wendy L Yarno is at least $1.3 Milione dollars as of 24 June 2024. Ms. Yarno owns over 3,350 units of Global Blood Therapeutics stock worth over $708,872 and over the last 11 years she sold GBT stock worth over $0. In addition, she makes $595,745 as Independent Director at Global Blood Therapeutics.
Sign up
Ms. Yarno GBT stock SEC Form 4 insiders trading
Wendy has made over 16 trades of the Global Blood Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 3,350 units of GBT stock worth $229,442 on 24 June 2024.
The largest trade she's ever made was exercising 19,000 units of Global Blood Therapeutics stock on 15 May 2023 worth over $1,301,310. On average, Wendy trades about 1,525 units every 41 days since 2013. As of 24 June 2024 she still owns at least 10,350 units of Global Blood Therapeutics stock.
You can see the complete history of Ms. Yarno stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wendy Yarno biography
Wendy L. Yarno serves as Independent Director of the Company. Ms. Yarno retired in September 2008 from Merck & Co, Inc. where she served in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer, before she retired. Prior to this position, Ms. Yarno served as General Manager for Merck’s Cardiovascular/Metabolic United States Business Unit and as Senior Vice President, Human Resources. From 2010 to 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company. Ms. Yarno currently serves on the boards of directors of the biopharmaceuticals companies Ideaya Biosciences, Inc., MyoKardia, Inc. and Inovio Pharmaceuticals, Inc. Ms. Yarno previously served as member of the board of directors of St. Jude Medical, Inc., Medivation, Inc., Alder Biopharmaceuticals, Inc., Aratana Biopharmaceuticals, Inc. and Durata Therapeutics, Inc. Ms. Yarno received an M.B.A. from Temple University, Fox School of Business, and a B.S. in business administration from Portland State University. Ms. Yarno’s qualifications to serve on our Board of Directors include her extensive experience commercializing pharmaceutical products, and her extensive operational and senior management experience, in the biopharmaceutical industry, as well as her experience serving on the board of directors (and certain key standing committees) of other biopharmaceutical companies.
What is the salary of Wendy Yarno?
As the Independent Director of Global Blood Therapeutics, the total compensation of Wendy Yarno at Global Blood Therapeutics is $595,745. There are 15 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
How old is Wendy Yarno?
Wendy Yarno is 65, she's been the Independent Director of Global Blood Therapeutics since 2017. There are 3 older and 18 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
What's Wendy Yarno's mailing address?
Wendy's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.
Insiders trading at Global Blood Therapeutics
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... e Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
What does Global Blood Therapeutics do?
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
What does Global Blood Therapeutics's logo look like?
Complete history of Ms. Yarno stock trades at Global Blood Therapeutics, Inovio Pharmaceuticals Inc, MyoKardia, Iovance Biotherapeutics Inc, IDEAYA Biosciences e Tarsus Pharmaceuticals
Global Blood Therapeutics executives and stock owners
Global Blood Therapeutics executives and other stock owners filed with the SEC include:
-
Ted Love,
President, Chief Executive Officer, Director -
Brian Cathers,
Chief Scientific Officer -
Tricia Suvari,
Chief Legal Officer -
Jung Choi,
Chief Business and Strategy Officer -
David Johnson,
Chief Commercial Officer -
Jeffrey Farrow,
Chief Financial Officer -
Dr. Ted W. Love,
Pres, CEO & Director -
Dr. Ted W. Love M.D.,
Pres, CEO & Director -
David L. Johnson,
Chief Commercial Officer -
Jeffrey S. Farrow,
CFO & Principal Accounting Officer -
Jung E. Choi,
Chief Bus. & Strategy Officer -
Dr. Kim Smith-Whitley M.D.,
Exec. VP and Head of R&D -
Patricia Borga Suvari,
Chief Legal Officer & Sec. -
Mark Perry,
Lead Independent Director -
Scott Morrison,
Independent Director -
Wendy Yarno,
Independent Director -
Deval Patrick,
Director -
Glenn Pierce,
Independent Director -
Philip Pizzo,
Independent Director -
Willie Brown,
Independent Director -
Dawn Svoronos,
Independent Director -
Eric Fink,
Chief Human Resource Officer -
Stephanie Yao,
Sr. Director of Corp. Communications & Investor Relations -
Nazila Habibizad,
Exec. VP of Operations -
Dr. Andrej Sali Ph.D.,
Founder & Advisor -
Dr. Matthew P. Jacobson Ph.D.,
Founder & Advisor -
Dr. David R. Phillips,
Founder & Advisor -
Lesley Ann Calhoun,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Ii, L.P.Third...,
-
Michael W Bonney,
Director -
Eleanor Ramos,
Chief Medical Officer -
Kevin P Starr,
Director -
Charles J Homcy,
Director -
Robert I Tepper,
10% owner -
Rock Ventures Ii, L.P.Starr...,
-
Hing Sham,
See Remarks -
Joshua Lehrer Graiwer,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Peter Radovich,
See Remarks -
Nazila Habibizad,
See Remarks -
John Schembri,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Iii, L.P.Thir...,
-
Carrie Krehlik,
Chief Human Resources Officer -
Alexis A. Thompson,
Director -
Kim Smith Whitley,
See Remarks